168 related articles for article (PubMed ID: 36884136)
1. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
Jin D; Qian L; Xia J; Zhang R; Yang G; Zhang L; Xue W; Cao M; Dong L; Chen H
Med Oncol; 2023 Mar; 40(4):113. PubMed ID: 36884136
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
7. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
8. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C
Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869
[TBL] [Abstract][Full Text] [Related]
12. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.
Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H
Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552
[TBL] [Abstract][Full Text] [Related]
13. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T
Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
15. PD-L1
Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
[TBL] [Abstract][Full Text] [Related]
17. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
Wang HL; Wu JQ; Wang Y; Yu J; Mao XN; Li ZR; Niu HR; Jin CL; Wang XJ; Yan ZH; Yi L; Yang B; Wei PJ; Zhang HT; Zhang SC
Neoplasma; 2021 Jul; 68(4):823-831. PubMed ID: 34097427
[TBL] [Abstract][Full Text] [Related]
19. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
[TBL] [Abstract][Full Text] [Related]
20. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
